Online inquiry

IVTScrip™ mRNA-Human ARPC5L, (Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK26272MR)

This product GTTS-WK26272MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the ARPC5L protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Human
RefSeq NM_030978.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 81873
UniProt ID Q9BPX5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARPC5L, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WK26272MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK13597MR IVTScrip™ mRNA-Human AC133, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AC133
GTTS-WK13075MR IVTScrip™ mRNA-Human ACTRT3, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACTRT3
GTTS-WK28666MR IVTScrip™ mRNA-Human ARPC1B, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARPC1B
GTTS-WK22296MR IVTScrip™ mRNA-Human ARHGAP32, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARHGAP32
GTTS-WK25013MR IVTScrip™ mRNA-Human ARHGEF2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGEF2
GTTS-WK28598MR IVTScrip™ mRNA-Human ARHGAP39, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP39
GTTS-WK13130MR IVTScrip™ mRNA-Human Additional GABA Compounds, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Additional GABA Compounds
GTTS-WK18070MR IVTScrip™ mRNA-Human AKIRIN2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AKIRIN2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW